Welcome to AMYPAD!

We were a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aimed to:

 💡 You can now make a formal request to access our data!


→ Access data


→ Our papers


Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
AMYPAD PNHS Procedure 13 Feb 2024 We provide an overview of the PNHS data accessibility, a snapshot of the year 2023, and a glimpse into the future....
Interview with Leonard Pieperhoff
Interview with Leonard Pieperhoff 12 Feb 2024 I am no working in Neuroimaging at the Amsterdam UMC since February 2023......
AMYPAD at AD/PD2024 11 Dec 2023 Leonard Pieperhoff will be presenting findings from the AMYPAD PNHS study at AD/PD2024....
"We would hope that the direct results of the project are useful about our thinking of when amyloid deposition starts and when it's clinically relevant. But what is even more important is that the consortium that we formed, started collaborating on things that go well beyond the initial goals of AMYPAD. And actually, we should further integrate AMYPAD, EPAD and all the European cohorts that are now collaborating and joining forces in analysis of PET/MRI scans, imaging, biomarker but also genetic data. It is something of great value and will contribute to the future of all samples, definitely in Europe and hopefully also globally. ” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.